Diabetes & Metabolism Journal最新文献_第8页

Construction of Risk Prediction Model of Type 2 Diabetic Kidney Disease Based on Deep Learning. 基于深度学习的 2 型糖尿病肾病风险预测模型的构建

IF 5.9 2区医学

Diabetes & Metabolism Journal Pub Date : 2024-04-30 DOI: 10.4093/dmj.2023.0033

Chuan Yun, Fangli Tang, Zhenxiu Gao, Wenjun Wang, Fang Bai, Joshua D Miller, Huanhuan Liu, Yaujiunn Lee, Qingqing Lou

引用次数: 0

Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial. 阿格列汀-吡格列酮联合治疗二甲双胍控制不佳的 2 型糖尿病的有效性和安全性：一项多中心、双盲随机试验。

IF 5.9 2区医学

Diabetes & Metabolism Journal Pub Date : 2024-04-23 DOI: 10.4093/dmj.2023.0259

Ji-Yeon Park, Joonyub Lee, Yoon-Hee Choi, Kyung-Wan Min, K. Han, Kyu-Jeung Ahn, Soo Lim, Young-Hyun Kim, Chul Woo Ahn, Kyung Mook Choi, Kun-Ho Yoon

{"title":"Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial.","authors":"Ji-Yeon Park, Joonyub Lee, Yoon-Hee Choi, Kyung-Wan Min, K. Han, Kyu-Jeung Ahn, Soo Lim, Young-Hyun Kim, Chul Woo Ahn, Kyung Mook Choi, Kun-Ho Yoon","doi":"10.4093/dmj.2023.0259","DOIUrl":"https://doi.org/10.4093/dmj.2023.0259","url":null,"abstract":"Background\u0000Guidelines for switching to triple combination therapy directly after monotherapy failure are limited. This study investigated the efficacy, long-term sustainability, and safety of either mono or dual add-on therapy using alogliptin and pioglitazone for patients with type 2 diabetes mellitus (T2DM) who did not achieve their target glycemic range with metformin monotherapy.\u0000\u0000\u0000Methods\u0000The Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) was a multicenter, placebo-controlled, double-blind, randomized trial. A total of 214 participants were randomized to receive alogliptin+pioglitazone (Alo+Pio group, n=70), alogliptin (Alo group, n=75), or pioglitazone (Pio group, n=69). The primary outcome was the difference in glycosylated hemoglobin (HbA1c) levels between the three groups at baseline to 24 weeks. For durability, the achievement of HbA1c levels <7% and <6.5% was compared in each group. The number of adverse events was investigated for safety.\u0000\u0000\u0000Results\u0000After 24 weeks of treatment, the change of HbA1c in the Alo+Pio, Alo, and Pio groups were -1.38%±0.08%, -1.03%±0.08%, and -0.84%±0.08%, respectively. The Alo+Pio group had significantly lower HbA1c levels than the other groups (P=0.0063, P<0.0001) and had a higher proportion of patients with target HbA1c achievement. In addition, insulin sensitivity and β-cell function, lipid profiles, and other metabolic indicators were also improved. There were no significant safety issues in patients treated with triple combination therapy.\u0000\u0000\u0000Conclusion\u0000Early combination triple therapy showed better efficacy and durability than the single add-on (dual) therapy. Therefore, combination therapy with metformin, alogliptin, and pioglitazone is a valuable early treatment option for T2DM poorly controlled with metformin monotherapy.","PeriodicalId":11153,"journal":{"name":"Diabetes & Metabolism Journal","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140671131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

DGAT2 Plays a Crucial Role to Control ESRRAPROX1 Transcriptional Network to Maintain Hepatic Mitochondrial Sustainability. DGAT2 在控制 ESRRAPROX1 转录网络以维持肝线粒体可持续性方面发挥着至关重要的作用。

IF 5.9 2区医学

Diabetes & Metabolism Journal Pub Date : 2024-04-22 DOI: 10.4093/dmj.2023.0368

Yoseob Lee, Yeseong Hwang, Minki Kim, Hyeonuk Jeon, Seyeon Joo, Sungsoon Fang, Jae-Woo Kim

引用次数: 0

Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism. 胰高血糖素样肽-1：脂质代谢的新调节器

IF 5.9 2区医学

Diabetes & Metabolism Journal Pub Date : 2024-04-01 DOI: 10.4093/dmj.2023.0277

Tong Bu, Ziyan Sun, Yi Pan, Xia Deng, G. Yuan

引用次数: 0

Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review. 非诺贝特在亚洲人血脂异常及相关并发症中的作用：叙述性综述。

IF 5.9 2区医学

Diabetes & Metabolism Journal Pub Date : 2024-03-01 Epub Date: 2024-01-26 DOI: 10.4093/dmj.2023.0168

Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang

{"title":"Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review.","authors":"Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang","doi":"10.4093/dmj.2023.0168","DOIUrl":"10.4093/dmj.2023.0168","url":null,"abstract":"Hypertriglyceridemia and decreased high-density lipoprotein cholesterol (HDL-C) persist despite statin therapy, contributing to residual atherosclerotic cardiovascular disease (ASCVD) risk. Asian subjects are metabolically more susceptible to hypertriglyceridemia than other ethnicities. Fenofibrate regulates hypertriglyceridemia, raises HDL-C levels, and is a recommended treatment for dyslipidemia. However, data on fenofibrate use across different Asian regions are limited. This narrative review summarizes the efficacy and safety data of fenofibrate in Asian subjects with dyslipidemia and related comorbidities (diabetes, metabolic syndrome, diabetic retinopathy, and diabetic nephropathy). Long-term fenofibrate use resulted in fewer cardiovascular (CV) events and reduced the composite of heart failure hospitalizations or CV mortality in type 2 diabetes mellitus. Fenofibrate plays a significant role in improving irisin resistance and microalbuminuria, inhibiting inflammatory responses, and reducing retinopathy incidence. Fenofibrate plus statin combination significantly reduced composite CV events risk in patients with metabolic syndrome and demonstrated decreased triglyceride and increased HDL-C levels with an acceptable safety profile in those with high CV or ASCVD risk. Nevertheless, care is necessary with fenofibrate use due to possible hepatic and renal toxicities in vulnerable individuals. Long-term trials and real-world studies are needed to confirm the clinical benefits of fenofibrate in the heterogeneous Asian population with dyslipidemia.","PeriodicalId":11153,"journal":{"name":"Diabetes & Metabolism Journal","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10995494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139562753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk of Depression according to Cumulative Exposure to a Low-Household Income Status in Individuals with Type 2 Diabetes Mellitus: A Nationwide Population- Based Study. 根据 2 型糖尿病患者累积暴露于低家庭收入状况的抑郁风险：一项基于全国人口的研究。

IF 5.9 2区医学

Diabetes & Metabolism Journal Pub Date : 2024-03-01 Epub Date: 2024-01-03 DOI: 10.4093/dmj.2022.0299

So Hee Park, You-Bin Lee, Kyu-Na Lee, Bongsung Kim, So Hyun Cho, So Yoon Kwon, Jiyun Park, Gyuri Kim, Sang-Man Jin, Kyu Yeon Hur, Kyungdo Han, Jae Hyeon Kim

{"title":"Risk of Depression according to Cumulative Exposure to a Low-Household Income Status in Individuals with Type 2 Diabetes Mellitus: A Nationwide Population- Based Study.","authors":"So Hee Park, You-Bin Lee, Kyu-Na Lee, Bongsung Kim, So Hyun Cho, So Yoon Kwon, Jiyun Park, Gyuri Kim, Sang-Man Jin, Kyu Yeon Hur, Kyungdo Han, Jae Hyeon Kim","doi":"10.4093/dmj.2022.0299","DOIUrl":"10.4093/dmj.2022.0299","url":null,"abstract":"Backgruound: We aimed to identify the risk of incident depression according to cumulative exposure to a low-household income status in individuals with type 2 diabetes mellitus (T2DM).Methods: For this retrospective longitudinal population-based cohort study, we used Korean National Health Insurance Service data from 2002 to 2018. Risk of depression was assessed according to cumulative exposure to low-household income status (defined as Medical Aid registration) during the previous 5 years among adults (aged ≥20 years) with T2DM and without baseline depression who underwent health examinations from 2009 to 2012 (n=2,027,317).Results: During an average 6.23 years of follow-up, 401,175 incident depression cases occurred. Advance in cumulative number of years registered for medical aid during the previous 5 years from baseline was associated with an increased risk of depression in a dose-dependent manner (hazard ratio [HR], 1.44 [95% confidence interval (CI), 1.38 to 1.50]; HR, 1.40 [95% CI, 1.35 to 1.46]; HR, 1.42, [95% CI, 1.37 to 1.48]; HR, 1.46, [95% CI, 1.40 to 1.53]; HR, 1.69, [95% CI, 1.63 to 1.74] in groups with 1 to 5 exposed years, respectively). Insulin users exposed for 5 years to a low-household income state had the highest risk of depression among groups categorized by insulin use and duration of low-household income status.Conclusion: Cumulative duration of low-household income status, defined as medical aid registration, was associated with an increased risk of depression in a dose-response manner in individuals with T2DM.","PeriodicalId":11153,"journal":{"name":"Diabetes & Metabolism Journal","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10995483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing Patient Outcomes: Prioritizing SGLT2is and GLP-1RAs in Diabetes with CVD. 提高患者疗效：在糖尿病合并心血管疾病患者中优先使用 SGLT2is 和 GLP-1RAs。

IF 5.9 2区医学

Diabetes & Metabolism Journal Pub Date : 2024-03-01 Epub Date: 2024-03-22 DOI: 10.4093/dmj.2024.0096

Gwanpyo Koh

引用次数: 0

One-Carbon Metabolism Nutrients, Genetic Variation, and Diabetes Mellitus. 一碳代谢营养素、遗传变异与糖尿病。

IF 5.9 2区医学

Diabetes & Metabolism Journal Pub Date : 2024-03-01 Epub Date: 2024-03-12 DOI: 10.4093/dmj.2023.0272

Jie Zhu, Gunjana Saikia, Xiaotao Zhang, Xiaoxi Shen, Ka Kahe

{"title":"One-Carbon Metabolism Nutrients, Genetic Variation, and Diabetes Mellitus.","authors":"Jie Zhu, Gunjana Saikia, Xiaotao Zhang, Xiaoxi Shen, Ka Kahe","doi":"10.4093/dmj.2023.0272","DOIUrl":"10.4093/dmj.2023.0272","url":null,"abstract":"Diabetes mellitus (DM) affects about 9.3% of the population globally. Hyperhomocysteinemia (HHcy) has been implicated in the pathogenesis of DM, owing to its promotion of oxidative stress, β-cell dysfunction, and insulin resistance. HHcy can result from low status of one-carbon metabolism (OCM) nutrients (e.g., folate, choline, betaine, vitamin B6, B12), which work together to degrade homocysteine by methylation. The etiology of HHcy may also involve genetic variation encoding key enzymes in OCM. This review aimed to provide an overview of the existing literature assessing the link between OCM nutrients status, related genetic factors, and incident DM. We also discussed possible mechanisms underlying the role of OCM in DM development and provided recommendations for future research and practice. Even though the available evidence remains inconsistent, some studies support the potential beneficial effects of intakes or blood levels of OCM nutrients on DM development. Moreover, certain variants in OCM-related genes may influence metabolic handling of methyl-donors and presumably incidental DM. Future studies are warranted to establish the causal inference between OCM and DM and examine the interaction of OCM nutrients and genetic factors with DM development, which will inform the personalized recommendations for OCM nutrients intakes on DM prevention.","PeriodicalId":11153,"journal":{"name":"Diabetes & Metabolism Journal","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10995489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140101284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of Measures of Glucose Metabolism with Colorectal Cancer Risk in Older Chinese: A 13-Year Follow-up of the Guangzhou Biobank Cohort Study-Cardiovascular Disease Substudy and Meta-Analysis (Diabetes Metab J 2024;48:134-45). 广州生物库队列研究-心血管疾病子研究13年随访及Meta分析》（Diabetes Metab J 2024;48:134-45广州生物库队列研究--心血管疾病子研究13年随访及Meta分析》（Diabetes Metab J 2024;48:134-45）。

IF 5.9 2区医学

Diabetes & Metabolism Journal Pub Date : 2024-03-01 Epub Date: 2024-03-22 DOI: 10.4093/dmj.2024.0070

Jin Hwa Kim

引用次数: 0

Association of Measures of Glucose Metabolism with Colorectal Cancer Risk in Older Chinese: A 13-Year Follow-up of the Guangzhou Biobank Cohort Study-Cardiovascular Disease Substudy and Meta-Analysis (Diabetes Metab J 2024;48:134-45). 广州生物库队列研究-心血管疾病子研究13年随访及Meta分析》（Diabetes Metab J 2024;48:134-45广州生物库队列研究--心血管疾病子研究13年随访及Meta分析》（Diabetes Metab J 2024;48:134-45）。

IF 5.9 2区医学

Diabetes & Metabolism Journal Pub Date : 2024-03-01 Epub Date: 2024-03-22 DOI: 10.4093/dmj.2024.0085

Shu Yi Wang, Lin Xu

引用次数: 0